ArticleFrontiers in psychiatry2025
Uric acid and HDL-C-derived inflammatory ratios as biomarkers in schizophrenia and major depressive disorder: a retrospective study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ratios derived from uric acid (UA) and high-density lipoprotein cholesterol (HDL-C) represent novel composite indicators integrating metabolic and inflammatory information. These ratios include the uric acid-to-lymphocyte ratio (ULR), uric acid-to-HDL-C ratio (UHR), uric acid-to-creatinine ratio (UCR), uric acid-to-albumin ratio (UAR), neutrophil-to-HDL-C ratio (NHR), lymphocyte-to-HDL-C ratio (LHR), monocyte-to-HDL-C ratio (MHR), and platelet-to-HDL-C ratio (PHR). This retrospective study aimed to evaluate and compare the predictive ability of these indicators in distinguishing patients with schizophrenia (SCZ) or major depressive disorder (MDD) from healthy controls (HCs) to identify potential biomarkers. Materials and methods: Blood parameter data were collected from 442 patients with SCZ, 326 with MDD, and 222 healthy controls. A retrospective analysis was conducted to examine intergroup differences in the UA- and HDL-C-derived ratios. The predictive efficacy of these parameters was assessed using receiver operating characteristic (ROC) curve analysis. Results: Significant intergroup differences in biomarker levels were observed. The UHR, UAR, NHR, and MHR were identified as predictive factors for distinguishing the SCZ group from the HC group, while the UAR and MHR distinguished the MDD group from the HC group. A composite model of the UHR, UAR, NHR, and MHR in the SCZ group yielded an area under the curve (AUC) of 0.877 (p<0.001). Similarly, a composite model of the UAR, UCR, UHR, and MHR in the MDD group produced an AUC of 0.818 (p<0.001). Conclusion: This study indicated that the ratio derived from UA and HDL-C more comprehensively reflects the inflammatory and metabolic status, and its expression differences can significantly distinguish SCZ and MDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.